HighTower Advisors LLC Sells 10,656 Shares of Cencora, Inc. $COR

HighTower Advisors LLC cut its stake in shares of Cencora, Inc. (NYSE:COR) by 8.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 118,624 shares of the company’s stock after selling 10,656 shares during the period. HighTower Advisors LLC’s holdings in Cencora were worth $37,073,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of COR. Vanguard Group Inc. lifted its holdings in shares of Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares in the last quarter. Geode Capital Management LLC lifted its position in Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after purchasing an additional 284,229 shares during the period. Norges Bank acquired a new stake in shares of Cencora during the 2nd quarter worth approximately $695,215,000. Viking Global Investors LP lifted its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Finally, Amundi lifted its stake in Cencora by 17.0% in the 2nd quarter. Amundi now owns 1,720,278 shares of the company’s stock valued at $500,893,000 after purchasing an additional 249,742 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by company insiders.

Cencora Price Performance

COR opened at $359.98 on Wednesday. The business’s fifty day simple moving average is $348.42 and its 200-day simple moving average is $329.91. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12-month low of $237.71 and a 12-month high of $377.54. The company has a market capitalization of $70.03 billion, a price-to-earnings ratio of 43.27, a PEG ratio of 1.66 and a beta of 0.68.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.73 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on COR shares. Barclays lifted their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday. Evercore cut their price target on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. TD Cowen lifted their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, UBS Group increased their price objective on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $399.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.